TY  - JOUR
AU  - Fábián, Anna
AU  - Bor, Renáta
AU  - Vasas, Béla
AU  - Szűcs, Mónika
AU  - Tóth, Tibor
AU  - Bősze, Zsófia
AU  - Szántó, Kata Judit
AU  - Bacsur, Péter
AU  - Bálint, Anita
AU  - Farkas, Bernadett
AU  - Farkas, Klaudia
AU  - Milassin, Ágnes
AU  - Rutka, Mariann
AU  - Resál, Tamás
AU  - Molnár, Tamás
AU  - Szepes, Zoltán
TI  - Long-term outcomes after endoscopic removal of malignant colorectal polyps. Results from a 10-year cohort
TS  - Results from a 10-year cohort
JF  - WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY
J2  - WORLD J GASTROINTEST ENDOSC
VL  - 16
PY  - 2024
IS  - 4
SP  - 193
EP  - 205
PG  - 13
SN  - 1948-5190
DO  - 10.4253/wjge.v16.i4.193
UR  - https://m2.mtmt.hu/api/publication/34852892
ID  - 34852892
AB  - Choosing an optimal post-polypectomy management strategy of malignant colorectal polyps is challenging, and evidence regarding a surveillance-only strategy is limited.To evaluate long-term outcomes after endoscopic removal of malignant colorectal polyps.A single-center retrospective cohort study was conducted to evaluate outcomes after endoscopic removal of malignant colorectal polyps between 2010 and 2020. Residual disease rate and nodal metastases after secondary surgery and local and distant recurrence rate for those with at least 1 year of follow-up were investigated. Event rates for categorical variables and means for continuous variables with 95% confidence intervals were calculated, and Fisher's exact test and Mann-Whitney test were performed. Potential risk factors of adverse outcomes were determined with univariate and multivariate logistic regression models.In total, 135 lesions (mean size: 22.1 mm; location: 42% rectal) from 129 patients (mean age: 67.7 years; 56% male) were enrolled. The proportion of pedunculated and non-pedunculated lesions was similar, with en bloc resection in 82% and 47% of lesions, respectively. Tumor differentiation, distance from resection margins, depth of submucosal invasion, lymphovascular invasion, and budding were reported at 89.6%, 45.2%, 58.5%, 31.9%, and 25.2%, respectively. Residual tumor was found in 10 patients, and nodal metastasis was found in 4 of 41 patients who underwent secondary surgical resection. Univariate analysis identified piecemeal resection as a risk factor for residual malignancy (odds ratio: 1.74; P = 0.042). At least 1 year of follow-up was available for 117 lesions from 111 patients (mean follow-up period: 5.59 years). Overall, 54%, 30%, 30%, 11%, and 16% of patients presented at the 1-year, 3-year, 5-year, 7-year, and 9-10-year surveillance examinations. Adverse outcomes occurred in 9.0% (local recurrence and dissemination in 4 patients and 9 patients, respectively), with no difference between patients undergoing secondary surgery and surveillance only.Reporting of histological features and adherence to surveillance colonoscopy needs improvement. Long-term adverse outcome rates might be higher than previously reported, irrespective of whether secondary surgery was performed.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Pallagi, Petra
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 18
PY  - 2024
IS  - Supplement_1
SP  - i869
EP  - i869
PG  - 1
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjad212.0551
UR  - https://m2.mtmt.hu/api/publication/34538603
ID  - 34538603
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Pallagi, Petra
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases
JF  - JOURNAL OF CROHNS & COLITIS
J2  - J CROHNS COLITIS
VL  - 18
PY  - 2024
IS  - 3
SP  - 392
EP  - 405
PG  - 14
SN  - 1873-9946
DO  - 10.1093/ecco-jcc/jjad160
UR  - https://m2.mtmt.hu/api/publication/34167015
ID  - 34167015
N1  - Ladon Therapeutics Ltd, Szeged, Hungary            
            Department of Medicine, University of Szeged, Szeged, Hungary            
            ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Szeged, Hungary            
            HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged, Szeged, Hungary            
            Faculty of Medicine, Institute of Laboratory Medicine, University of Szeged, Szeged, Hungary            
            Export Date: 8 April 2024            
            Correspondence Address: Maléth, J.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary; email: maleth.jozsef@med.uszeged.hu            
            Correspondence Address: Farkas, K.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary            
            Chemicals/CAS: adalimumab, 331731-18-1, 1446410-95-2; azathioprine, 446-86-6, 55774-33-9; budesonide, 51333-22-3, 51372-29-3; cyclosporine, 59865-13-3, 63798-73-2, 79217-60-0; infliximab, 170277-31-3; mesalazine, 89-57-6; plasminogen activator inhibitor 1, 140208-23-7; tofacitinib, 477600-75-2, 540737-29-9; ustekinumab, 815610-63-0, 949907-93-1; vedolizumab, 943609-66-3; Biomarkers; Plasminogen Activator Inhibitor 1            
            Tradenames: 201170, Greiner; ab269373, Abcam; ChemiDoc MP, Biorad; GraphPad 9.5.0, Graphpad; iScript cDNA Synthesis Kit, Biorad; MedCalc Software 20.211, MedCalc; Multiskan FC, Thermo; NucleoSpin RNA Plus Kit, Macherey            
            Manufacturers: Abcam; Biorad; Carl Zeiss; Graphpad; Greiner; Macherey; MedCalc; Thermo
AB  - Crohn's disease and ulcerative colitis require lifelong treatment and patient monitoring. Current biomarkers have several limitations, therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease (IBD). Previously, the role of plasminogen activator inhibitor 1 (PAI-1) was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyze the selectivity of PAI-1 in IBD, its correlation with the disease activity, and its potential to predict therapeutic response.Blood, colon biopsy, organoid cultures (OC), and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localization in serum, biopsy, and fecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively.The study population comprised 132 IBD patients (56 CD and 76 UC) and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentration is elevated in IBD patients, showing clinical and endoscopic activity. In responders (decrease of eMayo≥3 in UC; or SES-CD>50% in CD), the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not other organic gastrointestinal diseases.The serum, mucosal, and faecal PAI-1 concentration correlates with the disease activity and therapeutic response in IBD, suggesting that PAI-1 could be utilized as a novel non-invasive, disease-specific faecal biomarker in the patient follow-up.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - LDN-051 a novel fecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases – results of a phase 2 clinical trial
JF  - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
J2  - UEG JOURNAL
VL  - 11
PY  - 2023
IS  - S8
SP  - 291
EP  - 292
PG  - 2
SN  - 2050-6406
UR  - https://m2.mtmt.hu/api/publication/34593890
ID  - 34593890
LA  - English
DB  - MTMT
ER  - 

TY  - THES
AU  - Szántó, Kata Judit
TI  - Crucial steps for treatment optimization and decision making in inflammatory bowel disease management [A terápia optimalizálását és a döntéshozatalt befolyásoló tényezők a gyulladásos bélbetegségek kezelése során]
PB  - Szegedi Tudományegyetem
PY  - 2023
SP  - 53
DO  - 10.14232/phd.11527
UR  - https://m2.mtmt.hu/api/publication/34113040
ID  - 34113040
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Resál, Tamás
AU  - Bacsur, Péter
AU  - Horváth, Miklós
AU  - Szántó, Kata Judit
AU  - Rutka, Mariann
AU  - Bálint, Anita
AU  - Fábián, Anna
AU  - Bor, Renáta
AU  - Szepes, Zoltán
AU  - Fekete, János Tibor
AU  - Farkas, Klaudia
AU  - Miheller, Pál
AU  - Molnár, Tamás
TI  - Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.
JF  - THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
J2  - THER ADV GASTROENTER
VL  - 16
PY  - 2023
PG  - 14
SN  - 1756-283X
DO  - 10.1177/17562848231183529
UR  - https://m2.mtmt.hu/api/publication/34071361
ID  - 34071361
N1  - Supplemental material for this article is available online.
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has complicated the management of inflammatory bowel diseases (IBD).This study aimed to assess the efficacy of different anti-SARS-CoV-2 vaccines under different treatments in IBD patients and identify predictive factors associated with lower serological response, including anti-tumor necrosis factor (anti-TNF) drug levels.A prospective, double-center study of IBD patients was conducted following messenger ribonucleotide acid (mRNA) and non-mRNA anti-SARS-CoV-2 vaccination.Healthy control (HC) patients were enrolled to reduce bias. Baseline and control samples were obtained 14 days after the second dose to assess the impact of conventional and biological treatments. Clinical and biochemical activity, serological response level, and anti-TNF drug levels were measured.This study included 199 IBD (mean age, 40.9 ± 12.72 years) and 77 HC participants (mean age, 50.3 ± 12.36 years). Most patients (76.9%) and all HCs received mRNA vaccines. Half of the IBD patients were on biological treatment (anti-TNF 68.7%). Biological and thiopurine combined immunomodulation and biological treatment were associated with lower serological response (p < 0.001), and mRNA vaccination promoted better antibody levels (p < 0.001). Higher adalimumab levels caused lower serological response (p = 0.006). W8 persistence of anti-SARS-CoV-2 level was equal in IBD and HC groups. Vaccination did not aggravate clinical disease activity (p = 0.65).Anti-SARS-CoV-2 vaccination is considerably efficacious in IBD patients, with mRNA vaccines promoting better antibody levels. The negative impact of combined biological treatment, especially with high adalimumab drug levels, on serological response to vaccination should be considered. Although midterm durability of vaccination is encouraging, more data are needed to expand the existing understanding on this issue.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bacsur, Péter
AU  - Rutka, Mariann
AU  - Asbóth, András
AU  - Resál, Tamás
AU  - Szántó, Kata Judit
AU  - Jójárt, Boldizsár
AU  - Bálint, Anita
AU  - Ari, Eszter
AU  - Ajibola, Walliyulahi
AU  - Kintses, Bálint
AU  - Fehér, Tamás
AU  - Pigniczki , Daniella
AU  - Bor, Renáta
AU  - Fábián, Anna
AU  - Maléth, József
AU  - Szepes, Zoltán
AU  - Farkas, Klaudia
AU  - Molnár, Tamás
TI  - Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
JF  - THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
J2  - THER ADV GASTROENTER
VL  - 16
PY  - 2023
PG  - 13
SN  - 1756-283X
DO  - 10.1177/17562848231174298
UR  - https://m2.mtmt.hu/api/publication/34014839
ID  - 34014839
N1  - "Asbóth Andrásnál tévesen szerepel a publikáción az SZTE/TTIK/BI/Biokémiai és Molekuláris Biológiai Tanszék. (SE, SZTE admin5)"
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Jójárt, Boldizsár
AU  - Resál, Tamás
AU  - Kata, Diána
AU  - Molnár, Tünde
AU  - Bacsur, Péter
AU  - Szabó, Viktória
AU  - Varga, Árpád
AU  - Szántó, Kata Judit
AU  - Földesi, Imre
AU  - Molnár, Tamás
AU  - Maléth, József
AU  - Farkas, Klaudia
TI  - Plasminogen activator inhibitor 1 - a novel potential biomarker in inflammatory bowel diseases
JF  - CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE
J2  - CENT EUR J GASTRO HEPATOL
VL  - 9
PY  - 2023
IS  - Suppl. 1
SP  - 85
EP  - 85
PG  - 1
SN  - 2415-9107
UR  - https://m2.mtmt.hu/api/publication/34012213
ID  - 34012213
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Resál, Tamás
AU  - Mangó, Katalin
AU  - Bacsur, Péter
AU  - Szántó, Kata Judit
AU  - Pigniczki , Daniella
AU  - Keresztes, Csilla
AU  - Rutka, Mariann
AU  - Bálint, Anita
AU  - Milassin, Ágnes
AU  - Bor, Renáta
AU  - Fábián, Anna
AU  - Szepes, Zoltán
AU  - Farkas, Klaudia
AU  - Monostory, Katalin
AU  - Molnár, Tamás
TI  - Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone
JF  - EXPERT OPINION ON DRUG SAFETY
J2  - EXPERT OPIN DRUG SAF
VL  - 22
PY  - 2023
IS  - 6
SP  - 517
EP  - 524
PG  - 8
SN  - 1474-0338
DO  - 10.1080/14740338.2023.2181336
UR  - https://m2.mtmt.hu/api/publication/33697762
ID  - 33697762
N1  - Funding Agency and Grant Number: New National Excellence Program of the Ministry of Human Capacities [UNKP-22-3-SZTE-233, 125377, 129266, 134863, BO/00598/19/5]; Hungarian Scientific Research; National Research, Development and Innovation Office [BO/00723/22]; Janos Bolyai Research Grant; Geza Hetenyi Research Grant; Albert Szent-Gyoergyi Medical School, University of Szeged;  [UNKP-22-3-SZTE-278];  [UNKP-22-5-SZTE-545];  [UNKP-22-4 -SZTE-296];  [UNKP-21-5-SZTE-552]
            Funding text: This work was supported by the research grants of the Hungarian Scientific Research (K22-143549) National Research, Development and Innovation Office (Grant ID: 125377, 129266 and 134863), by the New National Excellence Program of the Ministry of Human Capacities (UNKP-22-3-SZTE-278 to T Resal, UNKP-22-5-SZTE-545 to R Bor, UNKP-22-4 -SZTE-296 to A Fabian, UNKP-21-5-SZTE-552 to K Farkas, UNKP-22-3-SZTE-233 to P Bacsur), and Janos Bolyai Research Grant (BO/00598/19/5 to K Farkas and BO/00723/22 to R Bor) and the Geza Hetenyi Research Grant (to K Farkas, M Rutka and A Balint) by the Albert Szent-Gyoergyi Medical School, University of Szeged.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Dávid, Anett
AU  - Szántó, Kata Judit
AU  - Fábián, Anna
AU  - Resál, Tamás
AU  - Farkas, Klaudia
AU  - Hallgató, Emese
AU  - Miheller, Pál
AU  - Sarlós, Patrícia
AU  - Molnár, Tamás
AU  - Rafael, Beatrix
TI  - Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
JF  - PRZEGLAD GASTROENTEROLOGICZNY
J2  - PRZ GASTROENTEROL
VL  - 18
PY  - 2023
IS  - 3
SP  - 334
EP  - 343
PG  - 10
SN  - 1895-5770
DO  - 10.5114/pg.2023.131398
UR  - https://m2.mtmt.hu/api/publication/33667439
ID  - 33667439
N1  - Department of Medicine, University of Szeged, Szeged, Hungary            
            Institute of Psychology, University of Szeged, Szeged, Hungary            
            1st Department of Surgery, Semmelweis University, Budapest, Hungary            
            Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary            
            Department of Preventive Medicine, University of Szeged, Szeged, Hungary            
            Export Date: 28 November 2023            
            Correspondence Address: Molnár, T.; Department of Medicine, Hungary; email: molnar.tamas@med.u-szeged.hu
LA  - English
DB  - MTMT
ER  -